

Offering eye health innovation and quality for our customers



INDEX

ABOUT US >

DRY EYE DISEASE >

PRESERVATIVE FREE OCULAR LUBRICANTS > *Dry eye syndrome* >

- Xailin® Traditional Product Range
- NEW Xailin® Eye Health Line
- VisuXL®
- VisuXL® Gel
- VisuEVO®

OCULAR ALLERGY / EYE IRRITATION >

- VisuECTOINE®

FOOD SUPPLEMENTS > *Retinal health* >

- VISUCOMPLEX™ Plus MAQUIBRIGHT®

FOOD SUPPLEMENTS > *Retinal ganglion cells protection* >

- COQUN® OS
- COQUN® combo

COMPLEMENTARY THERAPY > *Glaucoma disease* >

- COQUN® Eye Drops

FOOD SUPPLEMENTS > *Retinal protection* >

- HYDROFTA
- VISIOPREV
- VISIOPREV DUO

ABOUT US

VISUfarma is a pan-European ophthalmic pharmaceutical company with a clear mission: to bring quality products and global therapeutic innovation to European eye health. We are an ambitious and fast growing ophthalmology company, commercializing a broad portfolio of pharmaceutical products and medical devices across Europe. (www.VISUfarma.com).


The company was formed in 2016 and is the result of the successful combination of the Italian company Visufarma SpA and the commercial activities of the international Nicox SA, headquartered in France. The combination created VISUfarma.

We offer a complete portfolio of products in the areas of : dry eye, eyelid hygiene, meibomian gland dysfunction (MGD), blepharitis & demodex management, retinal health, food supplements and glaucoma.

Our growing portfolio of innovative products, and our commitment to ocular health, will bring new therapeutic solutions from around the world to help patients across Europe and in 20+ countries worldwide through exclusive distributors.

VISUfarma has over 150 employees and two Business Units, one based in Amsterdam supporting all European countries (except Italy) and our distributors, and the other based in Rome dedicated to the Italian market and the international R&D.

VISUfarma has a strong commercial presence in 5 European countries and in 20+ countries through exclusive distributors.



DRY EYE DISEASE

The new definition of dry eye as well as a new classification system are contained in the Film & Ocular Surface Society (TFOS) Dry Eye Workshop II (DEWS II) report which was published on July 21, 2017. It has impacted the way the disease is diagnosed and examined.

THE UPDATED DEFINITION¹

“Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles”

- The management of dry eye disease (DED) remains something of an art, not easily lending itself to a rigid, evidence-based algorithm that accomodates all patients with dry eye symptoms and signs.
- For patients who do not respond to a given level of management, or who exhibit more severe DED, may need extra management and in some cases, the previous therapy may be continued, in addition to any new therapies.
- The VISUfarma portfolio offers a variety of products to help manage different types of symptoms caused by dry eye disease and their management.

Staged management & treatment recommendations for dry eye disease (Step 1 & Step 2) ¹	
Step 1	VISUfarma products
<ul style="list-style-type: none">• Education regarding the condition, its management, treatment and prognosis• Modification of local environment• Education regarding potential dietary modifications• Education and potential modification/ elimination of offending systematic and topical medications	Hydrofta®
Ocular lubricants of various types	Xailin® Fresh, Gel, Hydrate, HA, VisuXL®, VisuXL® Gel, VisuEVO®
Lid hygiene and warm compresses of various types	Naviblef® Dailycare, Visunet®, Meibopatch®, Xailin® Wash
Step 2: If above options are inadequate consider:	VISUfarma products
Non-preserved ocular lubricants to minimize preservative-induced toxicity	Xailin Fresh®, VisuXL®, VisuXL® Gel, VisuEVO®
Tea tree oil treatment for Demodex (if present)	Naviblef® Dailycare, Naviblef® Intensive Care, Naviblef® Wipes
Tear conservation	
Overnight treatments (such as ointment)	Xailin® Night
In-office,physical heating and expression of the meibobian glands	
Prescription drugs	

PRESERVATIVE FREE OCULAR LUBRICANTS

Dry eye syndrome



Xailin® Traditional Product Range

Our comprehensive range of **Xailin®** ocular lubricants helps relieve and refresh dry eyes and suits all of the dry eye patients' needs. Using widely prescribed, trusted ingredients all products in the range are preservative-free in the eye and are presented in easy-to-use, cost saving options.

The range includes:

- **Xailin® Hydrate** (Hypromellose 0.3%) Preservative-free in the eye 10ml bottle²
- **Xailin® Gel** (Carbomer 0.2%) Preservative-free in the eye gel 10g tube³
- **Xailin® Fresh** (Carmellose 0.5%) Preservative-free unit dose vials 30 x 0.4ml⁴
- **Xailin® HA** (Sodium Hyaluronate 0.2%) Preservative-free in the eye 10ml bottle⁵
- **Xailin® Night** (Soft White Paraffin, White Mineral oil, lanolin alcohols) Preservative-free eye ointment 5g tube⁶
- **Xailin® Wash** (Sodium chloride - 0.3%) Preservative-free single dose eye wash solution 20 x 5ml⁷



PRESERVATIVE FREE OCULAR LUBRICANTS

Dry eye syndrome

NEW Xailin®

Eye Health Line

A 3-product range of lubricating and moisturising eye drops, preservative and phosphate free

CROSS OUT dry eye with **VISUfarma's NEW Xailin® preservative and phosphate free formulation**, a customised solution for every individual's needs. Our 3-product range combines lubricating and moisturising eye drops with varying concentrations of sodium hyaluronate based on the severity of the dry eye condition and patient needs. All products in the range are preservative and phosphate **FREE**.

The range includes:

- **Xailin® TEARS** (0.1% HA) Lubricating eye drops with sodium hyaluronate 0.1% solution, preservative and phosphate **FREE**.⁸
- **Xailin® PLUS** (0.2% HA) Lubricating eye drops with sodium hyaluronate 0.2% solution, preservative and phosphate **FREE**.⁹
- **Xailin® INTENSE** (0.3% HA) Moisturising eye drops with sodium hyaluronate 0.3% solution, preservative and phosphate **FREE**.¹⁰



PRESERVATIVE FREE OCULAR LUBRICANTS

Dry eye syndrome

VisuXL®

The next generation eye drop for dry eye patients

VisuXL® is a lubricating and antioxidant solution without preservatives, composed of Coenzyme Q10, Vitamin E TPGS and cross-linked hyaluronic acid salt. The cross-linked hyaluronic acid is a more stable and effective form of hyaluronic acid than the linear form of HA and gives **VisuXL®** better viscoelastic, mucomimetic and moisturizing properties and is more effective over time.¹¹

VisuXL® is indicated for dry eye patients with trauma from a foreign body, alterations of ocular surface related to metabolic disorders (diabetes) or environmental stress (smog, chlorinated water, altered micro-climates, smoke, air conditioning, among others).¹¹ VisuXL® is available in a bottle of 5 ml and 10 ml without preservatives in 3K System and in 30 sterile unit dose containers of 0.33 ml, each 5 are available in a separate aluminum protective pouch, without preservatives.¹¹



ADVANCED HYDRATION¹²

Cross-linked HA has a residence time on ocular surface 3x longer than HA.*¹²



EFFECTIVE RESTORATION¹³

Patients treated with VisuXL® experience a highly statistically significant 4-fold reduction in corneal damage.¹³ VisuXL® helps to restore a healthy ocular surface.¹³



GREATER RELIEF¹³

Patients treated with VisuXL® experience greater relief compared to HA alone eye drops.¹³

**Based on animal model*



PRESERVATIVE FREE OCULAR LUBRICANTS

Dry eye syndrome

VisuXL® Gel

The next generation eye drop for dry eye patients who require a more intensive treatment

VisuXL® Gel is a **smart gel**¹⁴⁻¹⁷, transforming from a drop in the bottle to a gel in the eye. It is based on a unique combination of ingredients including Coenzyme Q10 (CoQ10), Cross-linked sodium carboxymethylcellulose (Cross-linked CMC) and Poloxamer 407.¹⁸

VisuXL® Gel is recommended for dry eye patients who require a more intensive treatment. Those with alterations in the continuity of the corneal and conjunctival surfaces after refractive corneal surgery and corneal transplant, alterations of ocular surface related to metabolic disorders (diabetes) or/and with prolonged exposure to computers, television and monitors in general. It is preservative free, contact lens friendly and is available in 10ml or 5ml comfort grip bottle which last 6 months.¹⁸



First smart gel¹⁴⁻¹⁷

It transforms from liquid into a gel when it comes in contact with the ocular surface, thanks to Poloxamer 407, a thermogelling agent.¹⁴⁻¹⁶ With VisuXL® Gel patients would experience all the benefits of traditional gels but in the convenience of a drop.



Day and night use¹⁸

Carboxymethyl Cellulose (CMC) has been cross-linked to form a hydrogel which increases lubrication and prolongs residence time.¹⁷ VisuXL® Gel provides day and night protection with just 2 drops.^{17,18*}



Long-lasting protection^{13,14*}

The Coenzyme Q10 (CoQ10) helps to repair damaged cells promoting a healthy ocular surface.^{19*,20*,21,22*} The cross-linked CMC captures the CoQ10 molecules and the increased residence time provides lasting protection.^{18,19*}

*Based on animal model



PRESERVATIVE FREE OCULAR LUBRICANTS

Dry eye syndrome

VisuEVO®

The first multitasking eye drop for patients suffering from Evaporative Dry Eye.

VisuEVO® is an innovative preservative free formulation containing **omega-3 essential fatty acids, Vitamin A, Vitamin D and ultra-filtered phospholipids.**²³

Due to the presence of phospholipids, omega-3 and Vitamin D, **VisuEVO®** restores the tear quality and reduces excessive evaporation of the tear film, which is caused by inflammatory conditions on the surface of the eye.²³

Vitamin A and phospholipids are natural constituents of the tear film, and their antioxidant action prevents damage caused by reactive oxygen species and facilitates homeostasis and the retention of the tear film.²³ Vitamin A and phospholipids control the evaporation of the tear film.²³

VisuEVO® is indicated for all patients suffering from evaporative dry eye, as pre-treatment for eye surgery, for forms of dry eye caused by a reduced secretion of lipids from the Meibomian glands, for cases of dry eye caused by a mucin deficiency.²³

VisuEVO® is contact lens friendly.²³

VisuEVO® comes in a bottle of 10 ml and 5 ml, preservative free in Novelia System®.²³



Reduces
excessive evaporation
of the tear film²³

Thanks to the presence of phospholipids, omega-3 and Vitamin D, VisuEVO® reduces excessive evaporation of the tear film, caused by inflammatory conditions on the surface of the eye.²³

Protects
from inflammatory
conditions²³

Omega-3, Vitamin D and phospholipids improve the osmolarity of the tear film, protecting it from inflammatory conditions caused by excessive evaporation.²³

Restores
the tear quality²³

Vitamin A and phospholipids facilitate homeostasis and the retention of the tear film, as well as the control of its evaporation.²³



OCULAR ALLERGY / EYE IRRITATION

VisuECTOINE®

The TRIPLE ACTION drop for ocular irritation and allergy

3 actives together for the first time

VisuECTOINE® is a humectant and lubricating sterile ophthalmic solution formulated with ectoine, sodium carboxymethylcellulose, and high molecular weight sodium hyaluronate.²⁴

VisuECTOINE® is indicated for ocular irritation produced by environmental factors (wind, dust, smoke, air conditioning, dry heat).²⁴ VisuECTOINE® protects against external allergens alleviating allergy symptoms.²⁴

VisuECTOINE® is preservative and phosphate free and can be used with contact lenses.²⁴ VisuECTOINE® is supplied in single-use containers made of low density polyethylene containing 0.4ml of the product. Each box contains 30 single-use containers.²⁴

VisuECTOINE® provides:

THREE FORCES AGAINST

EXTERNAL ALLERGENS



POLLEN



DUST MITES



ANIMAL HAIR



BACTERIUM

ENVIRONMENTAL FACTORS



POLLUTION



AIR



WIND



DRY HEAT



NATURAL PROTECTION^{24,25}



EFFECTIVE HYDRATION^{26,27}



LONG-LASTING RELIEF²⁸



PRESERVATIVE AND
PHOSPHATE FREE



SUSTAINED RELEASE
OF ECTOINE



FOOD SUPPLEMENTS

Retinal health

VISUCOMPLEX™ Plus MAQUIBRIGHT®

A step forward in retinal protection

VISUCOMPLEX™ Plus MAQUIBRIGHT® is a food supplement containing specific antioxidant, vitamin and mineral components that helps maintain vision by protecting retinal cells from oxidative stress induced by both UV light and the physiological processes of ageing.²⁹

VISUCOMPLEX™ Plus MAQUIBRIGHT® contains the innovative patented substance **MAQUIBRIGHT®** derived from the Maqui Berry plant (*Aristotelia chilensis*).²⁹

It also contains:

- **Alpha-lipoic acid:** provided in an innovative MATRIS RETARD controlled released format.
- **Copper:** contributes to the protection of cells from oxidative stress.
- **Zinc:** contributes to the maintenance of normal vision.
- **Vitamin E:** is an antioxidant which also has the property of maintenance of normal vision by protection of the lens of the eye.



Gluten and lactose free



PROTECT
Retinal cells against
oxidative stress



MAINTAIN
Normal Vision



EASY TO USE
1 caps per day

FOOD SUPPLEMENTS

Retinal ganglion cells protection

COQUN® OS

A food supplement with CoQ10

COQUN® OS is a food supplement based on Coenzyme Q10 Miniactives®, an innovative and patented modified and controlled release technology which allows the transport of Coenzyme Q10, favoring its absorption.³⁰ CoQ10 declines with age throughout the body³¹, therefore patients can benefit from the systemic absorption of CoQ10 from **COQUN® OS**.^{32,33}





Specifically designed to enhance absorption of CoQ10^{30,32,34}



Patient friendly^{34,35}



Well-tolerated³²



FOOD SUPPLEMENTS

Retinal ganglion cells protection

COQUN® combo

A new DUAL ACTION food supplement containing Coenzyme Q10 together with Citicoline

COQUN® combo is a new **DUAL ACTION** food supplement containing Coenzyme Q10 together with Citicoline in a unique and innovative high-quality tablet formulation. Thanks to its patented, innovative modified- and controlled-release **MINIACTIVES®** technology, **COQUN® combo** delivers Coenzyme Q10 and Citicoline in a way that boosts their absorption.³⁶

Coenzyme Q10 is a molecule which occurs in our bodies and is considered essential for the proper functioning of the mitochondria, the cell components responsible for producing energy in the body. The concentration of Coenzyme Q10 tends to decrease naturally with age and with neurodegenerative conditions, including those related to cells specialising in sight. **COQUN® combo** helps in maintaining normal levels of this key component.³⁶



Citicoline, the second component found within **COQUN® combo**, is a naturally-occurring molecule found within the body. It plays a key role in the synthesis of the elements that make up the nerve cell membrane as well as playing a part in the development of sight through efficient propagation of visual signals within the eye.³⁶



Coenzyme Q10 is considered essential for the proper functioning of the mitochondria, the cell components responsible for producing energy in the body.³⁶



Citicoline is a precursor in the endogenous synthesis of nerve cell membrane phospholipids.³⁶



With a modified and controlled-release technology that favours the absorption of Coenzyme Q10 and Citicoline.³⁶



COMPLEMENTARY THERAPY

Glaucoma disease

Glaucoma, a leading cause of blindness in the world, it is a progressive optic neuropathy often associated with increased intraocular pressure and characterized by progressive death of retinal ganglion cells (RGCs).³⁷ The European Glaucoma Society recognizes neuroprotection as an adjuvant treatment option in glaucoma³⁸ and there is evidence that coenzyme Q10 has a potential retinal neuroprotective action.^{37,39-41} Topical CoQ10 has proved to be an effective therapy preventing RGC apoptosis and losing glaucoma-related models.^{40*} This is due to its anti-apoptotic, antioxidant and bioenergetic properties.^{31,42}

COQUN® Eye Drops

Complementary treatment to antihypertensive glaucoma therapy

COQUN® eye drops contain CoQ10 and are specially formulated for patients with glaucoma. It is a complementary treatment to antihypertensive glaucoma therapy due to its capacity of counteracting the oxidative damages strictly related to this pathology.⁴³ It has been demonstrated that **COQUN®** can help improve retinal function.³⁷ **COQUN®** eye drops are preservative free, hypoallergenic, contact lens friendly and well tolerated.⁴³



Protect the retinal ganglion cells^{39*,41*,45}



Energise retinal function⁴⁴



Compatible with antihypertensive glaucoma therapy⁴³



COQUN® should never replace medically supervised glaucoma medication

**Based on experimental glaucoma studies in animal models*



FOOD SUPPLEMENTS

Retinal protection

The role of nutrition to support a healthy retina and overall eye health is well established. **VISUfarma** offers a comprehensive range of food supplements to help maintain ocular health.



VISUfarma in Italy has a broader portfolio of products for the following therapeutic categories:

- Glaucoma
- Antinflammatory (NSAID and SAID) and their combinations
- Antiallergic and decongestant
- Antifective

References

1. Adapted from Dry Eye Workshop II (DEWS II) report, July 21, 2017.
2. Xailin® Hydrate Instructions for Use, November 2016, VISUfarma.
3. Xailin® Gel Instructions for Use, December 2016, VISUfarma.
4. Xailin® Fresh Instructions for Use, February 2017, VISUfarma.
5. Xailin® HA Instructions for Use, December 2016, VISUfarma.
6. Xailin® Night Instructions for Use, December 2016, VISUfarma.
7. Xailin® Wash Instructions for Use, November 2012, VISUfarma.
8. Xailin® Tears Instructions for Use, September 2021, VISUfarma.
9. Xailin® Plus Instructions for Use, September 2021, VISUfarma.
10. Xailin® Intense Instructions for Use, September 2021, VISUfarma.
11. VisuXL® Instructions for Use, May 2018, VISUfarma.
12. Muzzi M, et al. Poster presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting. February 16-19, 2017. Florence, Italy.
13. Postorino E, et al. Efficacy of eye drops containing cross-linked hyaluronic acid and coenzyme Q10 treating patients with mild to moderate dry eye. Eur J Ophthalmol 2018;28(1):25-31.
14. Ibrahim SS. J Pharm Sci 2019; 108(6):1923-1933.
15. Almeida H, et al. Expert Opin Drug Deliv 2013; 10(9): 1223-1237.
16. Dumortier G, et al. Pharm Res 2006; 23(12): 2709-2728.
17. Kono H. Carbohydrate Polymers 2014; 106:84-93.
18. VisuXL® Gel Instructions for Use (IFU).
19. Brancato R, et al. J Refractive Surgery 2002; 18: 135-139.
20. Mencucci R, et al. Invest Ophthalmol Vis Sci 2014; 55: 7266-7271.
21. Gumus K. Eye Contact Lens 2017; 43(2):73-80.
22. Brancato R, et al. Eur J Ophthalmol 2000; 10(1): 32-38.
23. VisuEVO® Instructions for Use.
24. Instructions for use of VisuECTOINE®.
25. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease Dtsch Arztebl Int. 2015;112(5):71-82. doi:10.3238/arztebl.2015.0071.
26. Dwivedi, M., Brinkkötter, M., Harishchandra, R. K. & Galla, H. J. Biophysical investigations of the structure and function of the tear fluid lipid layers and the effect of ectoine. Part B: Artificial lipid films. Biochim. Biophys. Acta - Biomembr. (2014).
27. Bilstein, A., Heinrich, A., Rybachuk, A. & Mösges, R. Ectoine in the Treatment of Irritations and Inflammations of the Eye Surface. BioMed Research International (2021).
28. Eichel, A., Bilstein, A., Werkhäuser, N. & Mösges, R. Meta-Analysis of the Efficacy of Ectoine Nasal Spray in Patients with Allergic Rhinoconjunctivitis. J. Allergy (2014).
29. VISUCOMPLEXTM Plus Instructions for Use, VISUfarma (last revised December 2018).
30. COQUN® OS Instructions for Use, VISUfarma. [last revised 09/20].
31. Qu J et al. Invest Ophthalmol Vis Sci. 2009;50:1814-1818.
32. Martucci A et al. Nutrients. 2019;11(3):527.
33. VISUfarma Data on File. REF-00644. 2018.
34. Suractives®. Technical Data: MINIACTIVES® TECHNOLOGY. Accessed March 2019. http://suractives.com/test/wpcontent/uploads/2015/05/tecnologia_miniactives.pdf
35. VISUfarma Data on File. REF-00667.
36. COQUN® combo Instructions For Use.
37. Nucci C, Tartaglione R, Cerulli A, Mancino R, Spanò A, Cavaliere F, et al. Int Rev Neurobiol. 2007;82:397-406.
38. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th Edition. 2014.
39. Guo L, Cordeiro MF. Prog Brain Res. 2008;173:437-450.
40. Davis BM, Tian K, Pahlitzsch M, Brenton J, Ravindran N, Butt G, et al. Mitochondrion. 2017;36:114-123.
41. Noh YH, Kim KY, Shim MS, Choi SH, Choi S, Ellisman MH, et al. Cell Death Dis. 2013;4:e820.
42. Fato R et al. Acta Ophthalmol. 2010;88(4):e150-1.
43. COQUN® eye drops Instructions for Use, VISUfarma. [last revised 02/2020].
44. Parisi V et al. J Glaucoma 2014; 23(6): 391-404.
45. Lulli et al. Invest Ophthalmol Vis Sci. 2012;53(13):8295-8302.

* Based on animal model





Creating value in eye health for our patients worldwide

For more information about our company and products, please visit www.VISUfarma.com

Follow us on: **in**

